Tech Center 1600 • Art Units: 1612 1639 1675 1684
This examiner grants 29% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17911509 | SINGLE-CELL COMBINATORIAL INDEXED CYTOMETRY SEQUENCING | Non-Final OA | The Regents of the University of California |
| 17750844 | AFFINITY PURIFICATION SEQUENCING | Non-Final OA | The Regents of the University of California |
| 17785762 | NUCLEIC ACID ANALYSIS METHODS AND APPARATUS | Non-Final OA | BASF SE |
| 17938254 | Polynucleotide Barcodes for Multiplexed Proteomics | Non-Final OA | Singular Genomics Systems, Inc. |
| 18550004 | HIGH THROUGHOUT SCREENING IN DROPLETS | Non-Final OA | Novartis AG |
| 17843758 | METHODS TO GENERATE CIRCULARIZABLE PROBES IN SITU | Non-Final OA | 10x Genomics, Inc. |
| 17716134 | METHODS FOR ANALYTE DETECTION AND ANALYSIS | Non-Final OA | 10x Genomics, Inc. |
| 17476395 | SYSTEMS AND METHODS FOR BARCODE DESIGN AND DECODING | Non-Final OA | 10x Genomics, Inc. |
| 18181465 | SYSTEMS AND METHODS FOR BIOMOLECULE PREPARATION | Final Rejection | Nautilus Subsidiary, Inc. |
| 16735628 | SOLID-PHASE POLYMER SYNTHESIS ON REUSABLE SUBSTRATES | Final Rejection | MICROSOFT TECHNOLOGY LICENSING, LLC |
| 16936197 | FUNCTIONALIZED SOLID SUPPORT | Non-Final OA | Massachusetts Institute of Technology |
| 16625100 | HIGH-THROUGHPUT SINGLE-CELL TRANSCRIPTOME LIBRARIES AND METHODS OF MAKING AND OF USING | Non-Final OA | University of Washington |
| 17782805 | CELL PREPARATION WITH A SERIES OF DETECTION DEVICES | Non-Final OA | Hewlett-Packard Development Company, L.P. |
| 18305932 | COMPARTMENTALISED COMBINATORIAL CHEMISTRY BY MICROFLUIDIC CONTROL | Non-Final OA | UNITED KINGDOM RESEARCH AND INNOVATION |
| 18186449 | IMMUNOLOGICAL ANALYSIS METHODS | Non-Final OA | Becton, Dickinson and Company |
| 17165293 | Affinity Reagent and Catalyst Discovery Through Fiber-Optic Array Scanning Technology | Final Rejection | SRI International |
| 18033002 | COMPOSITIONS FOR AND METHODS OF CO-ANALYZING CHROMATIN STRUCTURE AND FUNCTION ALONG WITH TRANSCRIPTION OUTPUT | Non-Final OA | Duke University |
| 17178210 | PRECISION DRUG SCREENING FOR PERSONALIZED CANCER THERAPY | Final Rejection | Duke University |
| 18052337 | MODULAR NUCLEIC ACID ADAPTERS | Final Rejection | Roche Sequencing Solutions, Inc. |
| 17884594 | METHOD FOR ANALYZING CELL CLUSTERS | Non-Final OA | Yeda Research and Development Co. Ltd. |
| 18074790 | SINGLE CELL WHOLE GENOME LIBRARIES AND COMBINATORIAL INDEXING METHODS OF MAKING THEREOF | Final Rejection | Oregon Health & Science University |
| 17913189 | IMMUNOTHERAPEUTIC TARGETS IN MULTIPLE MYELOMA AND METHODS FOR THEIR IDENTIFICATION | Non-Final OA | THE TRUSTEES OF INDIANA UNIVERSITY |
| 18195763 | METHODS FOR NON-INVASIVE ASSESSMENT OF FETAL GENETIC VARIATIONS THAT FACTOR EXPERIMENTAL CONDITIONS | Non-Final OA | Sequenom, Inc. |
| 17922685 | COMPOSITIONS AND METHODS FOR IDENTIFYING NANOBODIES AND NANOBODY AFFINITIES | Non-Final OA | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 17912315 | METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 17919481 | Immune Cell Redirecting Compositions and Therapeutic Uses Thereof | Final Rejection | Children's Healthcare of Atlanta, Inc. |
| 18591921 | COMPOSITIONS AND METHODS FOR IDENTIFYING AND ISOLATING HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS | Final Rejection | THE BRIGHAM AND WOMEN'S HOSPITAL |
| 18173821 | NOVEL ANTIBODY LIBRARY PREPARATION METHOD AND LIBRARY PREPARED THEREBY | Non-Final OA | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION |
| 18021456 | FUNCTIONAL SCREENING USING DROPLET-BASED MICROFLUIDICS | Non-Final OA | Nankai University |
| 18269625 | BIOCHIP FOR SPATIAL TRANSCRIPTOMIC ANALYSIS, MANUFACTURING METHOD THEREFOR AND APPLICATION THEREOF | Non-Final OA | Celligent Biotechnology Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy